home / stock / nvs / nvs articles

NVS Articles, Novartis AG - From 10/03/23

Stock Information
Company Name: Novartis AG
Stock Symbol: NVS
Market: NYSE
Website: novartis.com
Menu
NVS NVS Quote NVS Short NVS News NVS Articles NVS Message Board
Get NVS Alerts

News, Short Squeeze, Breakout and More Instantly...
Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift | Benzinga

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Adva...
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration | Benzinga

All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of ...

Novartis' Investigational Therapy Shows Promising Action In Rare Kidney Disease | Benzinga

Novartis AG (NYSE: NVS) announced topline results from the pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study at nine months of...

Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer | Benzinga

Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in ...
Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside | Benzinga

JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid im...

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges | Benzinga

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY) for two undisclosed early-sta...

Health Insurer Centene Streamlines - Plans Massive Layoffs To Cut Costs: Report | Benzinga

Centene Corporation (NYSE: CNC) is reportedly laying off about 3% of its workforce as the health insurer plans to cut expenditures and acceler...
Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs | Benzinga

Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it e...

Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer | Benzinga

Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroe...

From Years to Months: How AI is Shaping the Landscape of Clinical Trials | Benzinga

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially ...
Previous 10 Next 10